Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06318507 · ClinicalTrials.gov registry record
The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
A clinical trial of Breast Neoplasms, sponsored by Pennington Biomedical Research Center.
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT06318507 is a study of Breast Neoplasms that is actively recruiting participants, run by Pennington Biomedical Research Center. The registered enrollment target is 25 participants, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06318507, a study of Breast Neoplasms, is actively recruiting participants, sponsored by Pennington Biomedical Research Center.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Fecal microbial diversity
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06318507
The ClinicalTrials.gov registry entry for NCT06318507 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Fecal microbial diversity is the first listed.
NCT06318507 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT06318507 about?
NCT06318507 is a clinical study titled "The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy". This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
What is the current status of trial NCT06318507?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-03-11. Estimated completion is 2026-12-31.
What conditions does trial NCT06318507 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT06318507?
The interventions under investigation include: Fecal microbial diversity (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06318507?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06318507 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Registry Study of Breast Microseed Treatment
RECRUITING
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.